Journal Article

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate

Paolisso, Giuseppe, Santamaria, Matteo, de Lucia, Claudio, Mauro, Ciro, Sardu, Celestino, Rizzo, Maria Rosaria, Marfella, Raffaele, Sacra, Cosimo, Barbieri, Michelangela, Paolisso, Pasquale, Ruocco, Antonio

2018

Overview

Objectives To evaluate clinical outcomes in patients with diabetes, treated by cardiac resynchronization therapy with a defibrillator (CRT-d), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) in addition to conventional hypoglycemic therapy vs. CRTd patients under conventional hypoglycemic drugs. Background Patients with diabetes treated by CRTd experienced an amelioration of functional New York Association Heart class, reduction of hospital admissions, and mortality, in a percentage about 60%. However, about 40% of CRTd patients with diabetes experience a worse prognosis. Materials and methods We investigated the 12-months prognosis of CRTd patients with diabetes, previously treated with hypoglycemic drugs therapy (n 271) vs. a matched cohort of CRTd patients with diabetes treated with GLP-1 RA in addition to conventional hypoglycemic therapy (n 288). Results At follow up CRTd patients with diabetes treated by GLP-1 RA therapy vs. CRTd patients with diabetes that did not receive GLP-1 RA therapy, experienced a significant reduction of NYHA class (p value < 0.05), associated to higher values of 6 min walking test (p value < 0.05), and higher rate of CRTd responders (p value < 0.05). GLP-1 RA patients vs. controls at follow up end experienced lower AF events (p value < 0.05), lower VT events (p value < 0.05), lower rate of hospitalization for heart failure worsening (p value < 0.05), and higher rate of CRTd responders (p value < 0.05). To date, GLP-1 RA therapy may predict a reduction of AF events (HR 0.603, CI [0.411–0.884]), VT events (HR 0.964, CI [0.963–0.992]), and hospitalization for heart failure worsening (HR 0.119, CI [0.028–0.508]), and a higher CRT responders rate (HR 3.707, CI [1.226–14.570]). Conclusions GLP-1 RA drugs in addition to conventional hypoglycemic therapy may significantly reduce systemic inflammation and circulating BNP levels in CRTd patients with diabetes, leading to a significant improvement of LVEF and of the 6 min walking test, and to a reduction of the arrhythmic burden. Consequently, GLP-1 RA drugs in addition to conventional hypoglycemic therapy may reduce hospital admissions for heart failure worsening, by increasing CRTd responders rate. Trial registration NCT03282136. Registered 9 December 2017 “retrospectively registered”

• Publisher: BioMed Central,BMC
• Subject: Aged / Angiology / Arrhythmias, Cardiac - diagnosis / Arrhythmias, Cardiac - mortality / Arrhythmias, Cardiac - physiopathology / Arrhythmias, Cardiac - therapy / Biomarkers - blood / Blood Glucose - drug effects / Blood Glucose - metabolism / Cardiac Resynchronization Therapy - adverse effects / Cardiac Resynchronization Therapy - mortality / Cardiac Resynchronization Therapy Devices / Cardiology / Defibrillators, Implantable / Diabetes / Diabetes Mellitus, Type 2 - blood / Diabetes Mellitus, Type 2 - diagnosis / Diabetes Mellitus, Type 2 - drug therapy / Diabetes Mellitus, Type 2 - mortality / Disease Progression / Electric Countershock - adverse effects / Electric Countershock - instrumentation / Electric Countershock - mortality / Female / Glucagon-Like Peptide-1 Receptor - agonists / Glucagon-Like Peptide-1 Receptor - metabolism / Heart Failure - diagnosis / Heart Failure - mortality / Heart Failure - physiopathology / Heart Failure - therapy / Humans / Hypoglycemic Agents - adverse effects / Hypoglycemic Agents - therapeutic use / Incretins - adverse effects / Incretins - therapeutic use / Italy / Male / Medicine / Medicine & Public Health / Middle Aged / Original Investigation / Patient Readmission / Prospective Studies / Recovery of Function / Risk Factors / Time Factors / Treatment Outcome / Ventricular Function, Left - drug effects